文献速递前列腺癌

近距离放疗单药治疗适合 favorable 和部分 unfavorable 中危前列腺癌

Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-09-11

该单中心回顾性分析纳入1622例中危前列腺癌患者,中位随访10.4年,评估近距离放疗单药治疗后的生化失败(BF)。单药治疗下,PSA≥10 ng/mL和cT2b-c疾病与BF相关;无这些风险因素者10年BF为5.8%,有者为17.2%。cT1-T2a/PSA<10组加ADT或EBRT均与BF无关;cT2b-T2c和/或PSA≥10亚组中ADT与BF相关而EBRT无关。

要点

  • 近距离放疗单药适用于所有favorable中危和cT1-T2a/PSA<10的unfavorable中危患者。
  • PSA≥10 ng/mL和cT2b-c疾病是单药治疗生化失败的独立风险因素。
  • cT2b-T2c和/或PSA≥10亚组中,加用ADT与生化失败降低相关,加用EBRT无显著关联。

核心结论

  • 近距离放疗单药治疗适合所有favorable中危和满足cT1-T2a/PSA<10标准的unfavorable中危前列腺癌。

研究设计与样本

  • 单中心回顾性分析纳入1622例中危前列腺癌患者,接受近距离放疗(单药或联合ADT和/或EBRT),中位随访10.4年。

主要发现

  • 单药治疗中,PSA≥10 ng/mL(调整sHR 3.01;95%CI 1.10-8.27;p=0.032)和cT2b-c疾病(调整sHR 4.52;95%CI 1.85-11.07;p=0.001)与生化失败相关。
  • 无上述风险因素者单药治疗后10年生化失败率为5.8%(FIR 3.8%,UIR 8.8%),有风险因素者为17.2%(FIR 9.3%,UIR 23.9%)。
  • cT1-T2a/PSA<10组中,加用ADT(sHR 0.90;95%CI 0.38-2.1;p=0.82)或EBRT(sHR 0.65;95%CI 0.36-1.18;p=0.16)与生化失败无关。
  • cT2b-T2c和/或PSA≥10亚组中,ADT(sHR 0.33;95%CI 0.14-0.74;p=0.007)与生化失败相关,EBRT(sHR 0.66;95%CI 0.34-1.31;p=0.24)无关。

关键数值与推荐

  • 生化失败定义为前列腺特异性抗原(PSA)>0.4 ng/mL。

临床怎么用

  • 对favorable中危及cT1-T2a/PSA<10的unfavorable中危患者可考虑近距离放疗单药治疗。
  • 对cT2b-T2c和/或PSA≥10的unfavorable中危患者,单药治疗生化失败风险较高,可考虑联合ADT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current National Comprehensive Cancer Network guidelines define brachytherapy monotherapy as a suitable treatment for favorable intermediate risk (FIR) and unfavorable intermediate risk (UIR) prostate cancer. Our objective is to define the subgroup of patients suitable for brachytherapy monotherapy. METHODS: We conducted a single-institutional retrospective analysis of intermediate risk prostate cancer, treated with brachytherapy with or without androgen deprivation therapy (ADT) and/or external beam radiation therapy (EBRT). The primary endpoint was biochemical failure (BF), defined as prostate specific antigen (PSA) > 0.4 ng/mL. For monotherapy, multivariate Fine-Gray analysis was used to identify risk factors associated with BF. Univariate analysis was performed to evaluate whether ADT and/or EBRT were associated with BF for patients without and with such factors. RESULTS: Among 1622 patients, the median follow-up was 10.4 years. For monotherapy, PSA ≥ 10 ng/mL (adjusted sHR 3.01; 95% CI: 1.10-8.27; p = 0.032) and cT2b-c disease (adjusted sHR 4.52; 95% CI: 1.85-11.07; p = 0.001) were associated with BF. The 10-year incidences of BF after monotherapy for patients without and with these risk factors were 5.8% (3.8% FIR, 8.8% UIR) versus 17.2% (9.3% FIR, 23.9% UIR), respectively. For the cT1-T2a/PSA < 10 risk group, neither the addition of ADT (sHR 0.90; 95% CI: 0.38-2.1; p = 0.82) nor EBRT (sHR 0.65; 95% CI: 0.36-1.18; p = 0.16) was associated with biochemical failure. For the cT2b-T2c and/or PSA ≥ 10 subgroup, ADT (sHR: 0.33; 95% CI: 0.14-0.74; p = 0.007) but not EBRT (sHR 0.66; 95% CI: 0.34-1.31; p = 0.24) was associated with BF. CONCLUSIONS: Brachytherapy monotherapy is suitable for all FIR, and UIR disease meeting cT1-T2a/PSA < 10 criteria.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. King M, Mirić G, Galbreath R, et al. Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 40935889. doi:10.1038/s41391-025-01021-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。